Wie hoch ist der Preis für Apexigen, Inc. (APGN)

Preis für Apexigen, Inc. (APGN) ist $0.385

Wie hoch ist die Marktkapitalisierung für Apexigen, Inc. (APGN)

Marktkapitalisierung für Apexigen, Inc. (APGN) ist $2.86M

Apexigen, Inc. (APGN) Operative Marge

Apexigen Inc., established in 2010 and based in San Carlos, California, is a clinical-stage biotechnology company dedicated to the discovery and advancement of antibody-based therapies for oncological diseases. The company's developmental pipeline features several promising candidates. A primary focus is APX005M, a humanized agonist antibody currently in Phase II clinical trials. This therapeutic agent is being explored for its efficacy against a variety of solid tumors, including melanoma, esophageal and gastroesophageal junction cancers, sarcoma, and rectal and ovarian malignancies, often in conjunction with other established treatments like immunotherapy, chemotherapy, radiation therapy, and cancer vaccines. Additionally, Apexigen is progressing APX601, a humanized antagonist antibody, through Phase I/II clinical trials for numerous tumor indications. Rounding out their experimental portfolio is APX801, an NK cell engager engineered to stimulate natural killer cells to eradicate cancerous cells.

Jahr	Operative Marge	ändert
Nicht genügend Daten für die angegebenen Daten.

Jahr

Operative Marge

ändert

Nicht genügend Daten für die angegebenen Daten.

Unternehmen	Operative Marge	Differenz der operativen Marge	Land
Vertex Pharmaceuticals Incorporated VRTX.US	38.59%	-	US
Argenx SE ARGX.US	28.81%	-	NL
Lonza Group AG LONN.SW	0.00%	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	0.00%	-	KR
UCB S.A. UCB.BR	31.23%	-	BE

Unternehmen

Operative Marge

Differenz der operativen Marge

Land